$CSTL

$33.30▲ +0.5% YTD

7 SEC 13D/G filings tracked · Last updated Oct 15, 2026

Filing History

CP $33.30▲ +0.5%Oct 15, 2026 · ThinkSabio Blog

$CSTL CSTL - Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026…

News

CSTL ▼ -5.0% - Castle Biosciences, Inc.

CP $32.76▲ -5.0%Oct 12, 2026 · ThinkSabio Blog

$CSTL CSTL - ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus…

News

CSTL ▲ +1.9% - Castle Biosciences, Inc.

CP $35.53▲ +1.9%Sep 30, 2026 · ThinkSabio Blog

$CSTL CSTL - Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management…

News

CSTL ▼ -0.1% - Castle Biosciences, Inc.

CP $35.81▲ -0.1%Sep 28, 2026 · ThinkSabio Blog

$CSTL CSTL - New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esopha…

News

CSTL ▼ -0.1% - Castle Biosciences, Inc.

CP $35.81▲ -0.1%Sep 28, 2026 · ThinkSabio Blog

$CSTL New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus…

News

CSTL ▼ -0.3% - Castle Biosciences, Inc.

CP $34.70▲ -0.3%Sep 24, 2026 · ThinkSabio Blog

$CSTL CSTL - New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx…

News

CSTL ▼ -1.1% - Castle Biosciences, Inc.

CP $32.31▲ -1.1%Sep 9, 2026 · ThinkSabio Blog

$CSTL CSTL - JAAD Publication Shows Improved Performance of DecisionDx®-SCC…